|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Myelodysplastic Syndromes | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Preleukemia | |||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Bone Marrow Diseases | |||||
| Disease | |||||
| Hematologic Diseases | |||||
| Neoplasms | |||||
| Pathologic Processes | |||||
| Precancerous Conditions | |||||
| 4 | Interventions listed in this trial | ||||
| lintuzumab | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Antibodies, Monoclonal | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| European Organization for Research and Treatment of Cancer | |||||